Ellie Guardino

TL;DR: T-DM1 significantly prolonged progression-free and overall survival with less toxicity than lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.

TL;DR: Clinically, T-DM1 has a consistent pharmacokinetics profile and minimal systemic exposure to free DM1, with no evidence of DM1 accumulation following repeated T- DM1 doses, and a few covariates were shown to affect interindividual variability in T-dm1 exposure and clearance in population-pharmacokinetics analyses.

TL;DR: First-line treatment with T-DM1 for patients with HER2-positive MBC provided a significant improvement in PFS, with a favorable safety profile, versus HT, in this randomized phase II study.

TL;DR: T-DM1 is well tolerated and has single-agent activity in patients with HER2-positive MBC who have previously received both approved Her2-directed therapies and multiple chemotherapy agents and may be an effective new treatment for this patient population.

TL;DR: In patients with treated, asymptomatic CNS metastases at baseline, T-DM1 was associated with significantly improved overall survival versus capecitabine–lapatinib and trastuzumab emtansine.